Stocks-BGNE-BeiGene Ltd-ADR

BGNE BeiGene Ltd-ADR

215.53 -2.67 (-1.22%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Stocks-BGNE-BeiGene Ltd-ADR
BGNE BeiGene Ltd-ADR
Invest

Performance

0% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
22.5B
Day’s Range
214.74
-
218.80
52W Range
119.89
-
279.58
Volume (3M)
233.75K
Price-Earnings Ratio
-11.07
Revenue
1.42B

BeiGene Ltd-ADR Latest News

View All
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health EquityBeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health EquityBioSpace2 days agoBeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024Forbes10 days agoBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New JerseyBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New JerseyBioSpace11 days ago
Pinned Post
Cancer-Med
United Kingdom
about a month ago
Pfizer in Early-Stage Talks to Acquire Seagen. 👉 $PFE (Pfizer) is reportedly in talks to acquire biotech $SGEN (Seagen Inc) , the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. Several hurdles would need to be overcome, including the potential... Show More
Like CommentShare
null
.
Top Discussions

About BeiGene Ltd-ADR

BeiGene Ltd is a global biopharmaceutical company with its headquarters in Beijing, China. The firm has offices in Cambridge Massachusetts and around the United States, as well as in Switzerland and across China. It has an expansive global clinical development program, with patients in 34 countries across five continents participating in a range of clinical trials. Founded in 2010, the firm employs over 5,000 people, with a clinical team of more than 1,600 professionals. BeiGene is engaged in the development and commercialisation of innovative molecularly-targeted and immune-oncology drugs for the treatment of various cancers. The firm is publicly traded on the NASDAQ GS where it is listed under the stock ticker BGNE. In January 2021, the BGNE price chart showed a 52-week high of $376.45 and a 52-week low of $118.55, with a market cap of $34.15bn. The company was originally founded as a small research and development company in China. In 2016, it became the first Chinese biotechnology firm to go public on the NASDAQ with an initial public offering worth $182m. A dual primary listing on the Hong Kong Stock Exchange in 2018 resulted in an IPO of $902m. Are you thinking of diversifying your investments on eToro? Start today by adding BGNE stock to your portfolio.
9K
Employees
George Town, George Town, US
HQ
2010
Founded
John V. Oyler, MBA
CEO
Show More
Med TechNASDAQ

Upcoming Earnings

4
MAY
REPORTS
BeiGene Ltd-ADR Q1 2023 earnings report is expected to be released before market open

Analyst Forecast

Consensus
Strong Buy
Price Target
311.00
Based on 3 analysts who covered BGNE 

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
57
High
Industry 
Avg. 47 
47
Environment
63
Social
54
Governance

People Also Bought